Most ZnO-nanostructure devices are fabricated using time-consuming nanomanipulation or one-by-one fabrication techniques, making them unattractive for large-scale production. Despite advantages in manufacturing cost and scalability, solutions-based processing has not produced high performing ZnO thin-film devices. This novel solutions-based process produces ZnO devices with shorter response times, lower device biases, and high light sensitivity.
This invention describes the first selective inhibitor of heat shock protein 90 kDa beta (Hsp90β). The invented inhibitor selectively binds to the N-terminus of Hsp90β and may be developed for the treatment of cancers. The inhibitor was developed based on the sequence alignment of the N-terminal ATP-binding domains of Hsp90α and Hsp90β complexed with a non-selective Hsp90 inhibitor, which revealed Hsp90β-specific residues that were key to exploit the selectivity of the new inhibitor.
Structural modification of a non-selective aminocyclohexanol-based heat shock protein 90 KDa (Hsp90) inhibitor led to a highly selective inhibitor of glucose regulated protein 94 kDa (Grp94). The new Grp94-selective inhibitor can be used to develop an effective therapy for the treatment of metastatic cancer and/or primary open angle glaucoma (POAG).
This novel process uses atomic layer deposition (ALD) to grow a tunnel barrier one atomic layer at a time. Placed between two electrically conducting materials, a tunnel barrier forms a tunnel junction. Electrons pass through the barrier by quantum tunneling. This process forms more uniform, thinner, and lower defect tunnel barriers. By improving the likelihood of quantum tunneling, this process creates higher performing tunnel junction devices.
A low-cost telemedicine tool featuring a virtual reality (VR) interface has been designed and developed to assist with the evaluation and diagnosis of neurodegenerative disease, thereby enabling greater access to care and earlier diagnosis for patients with neurological disorders; even for those in remote areas, or with limited transportation options.
Use of a genetic dereplication strategy eliminates major known SM biosynthetic pathways in Aspergillus nidulans, reducing the complexity of SM profiles and activating an abundance of silent SM gene clusters to enable identification of a new pool of fungal products for drug discovery.